Is depression associated with the risk of cardiovascular disease or vice versa?

Year 2020, Volume: 10 Issue: 4, 462 - 467, 30.12.2020

Erensu Baysak Feyza Arıcıoğlu

https://doi.org/10.33808/clinexphealthsci.824534

Abstract

The comorbidity between cardiovascular disease (CVD) and depression has been observed for many years. Several biological and behavioral hypotheses have been proposed to explain this comorbidity. However, the underlying common mechanisms are still unclear. Evidence suggests a bidirectional relationship between depression and CVD. Inflammation has been implicated in the etiology of both depression and CVD. In this review, we aim to increase awareness for CVD and depression comorbidity and provide some insights about the possible role of inflammation.

Keywords

major depression, cardiovascular disease, inflammation, hs-CRP

References

• Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nat Rev Dis Primers 2016;2(1):16065.
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 2013.
• Hwang JW, Egorova N, Yang XQ, Zhang WY, Chen J, Yang XY, Hu LJ, Sun S, Tu Y, Kong J. Subthreshold depression is associated with impaired resting-state functional connectivity of the cognitive control network. Transl Psychiatry 2015;5(11):e683-e.
• Malhi GS, Mann JJ. Depression. Lancet 2018;392(10161):2299-2312.
• Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr 2017;27:101-111.
• Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16(2):163-180.
• Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. The Am J Cardiol 2010;105(1 Suppl):3a-9a.
• Waldman SA, Terzic A. Cardiovascular health: the global challenge. Clin Pharmacol Ther 2011;90(4):483-5.
• Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J 2014;35(21):1365-72.
• Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R, Kutty VR, Wielgosz A, Lear S, AlHabib KF, Co HU, Lopez-Jaramillo P, et al. Association of symptoms of depression with cardiovascular disease and mortality in low-, middle-, and high-income countries. JAMA Psychiatry 2020;77(10):1052-1063.
• Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev 2011;19(3):130-42.
• Case SM, Sawhney M, Stewart JC. Atypical depression and double depression predict new-onset cardiovascular disease in U.S. adults. Depress Anxiety 2018;35(1):10-17.
• Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129(12):1350-69.
• Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry 2007;22(7):613-26.
• Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73(14):1827-1845.
• Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14(3):145-155.
• Wynn A. Unwarranted emotional distress in men with ischaemic heart disease (IHD). Med J Aust 1967;2(19):847-51.
• Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993:285-94.
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
• Wulsin LR, Evans JC, Vasan RS, Murabito JM, Kelly-Hayes M, Benjamin EJ. Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosom Med 2005;67(5):697-702.
• Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21(1):30-8.
• Janszky I, Ahlbom A, Hallqvist J, Ahnve S. Hospitalization for depression is associated with an increased risk for myocardial infarction not explained by lifestyle, lipids, coagulation, and inflammation: the SHEEP Study. Biol Psychiatry 2007;62(1):25-32.
• Holahan CJ, Pahl SA, Cronkite RC, Holahan CK, North RJ, Moos RH. Depression and vulnerability to incident physical illness across 10 years. J Affect Disord 2010;123(1-3):222-9.
• Nabi H, Kivimäki M, Empana JP, Sabia S, Britton A, Marmot MG, Shipley MJ, Singh-Manoux A. Combined effects of depressive symptoms and resting heart rate on mortality: the Whitehall II prospective cohort study. J Clin Psychiatry 2011;72(9):1199-206.
• Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak—the link between depression and cardiovascular disease. Nat Rev Cardiol 2012;9(9):526-39.
• Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB, Tatoulis J, Thompson DR, Tofler GH, Wilson A, Branagan MG. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust 2013;198(9):483-4.
• Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X, Wang Y, Xu X, Yin X, Deng J, Li L, Cao S, Lu Z. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry 2014;14:371.
• Khandaker GM, Zuber V, Rees JMB, Carvalho L, Mason AM, Foley CN, Gkatzionis A, Jones PB, Burgess S. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. Mol Psychiatry 2019;25(7):1477-1486.
• Halaris A. Inflammation-associated co-morbidity between depression and cardiovascular disease. Curr Top Behav Neurosci 2017;31:45-70.
• Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9(1):46-56.
• Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015;49:206-15.
• Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67(5):446-57.
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95.
• Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 2019;16(7):389-406.
• Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol 2017;14(3):133-144.
• Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond) 2018;132(12):1243-52.
• Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, frailty and cardiovascular disease. Adv Exp Med Biol 2020;1216:55-64.
• Nahrendorf M, Swirski FK. Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? Eur Heart J 2016;37(11):868-72.
• Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R. ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019;5(1):39.
• Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169(2):203-14.
• Herman FJ, Pasinetti GM. Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Brain Behav Immun 2018;73:66-84.
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377(12):1119-1131.
• Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380(8):752-762.
• Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013;111(10):1394-400.
• Mattina GF, Van Lieshout RJ, Steiner M. Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events. Ther Adv Cardiovasc Dis 2019;13:1753944719851950.
• Fioranelli M, Bottaccioli AG, Bottaccioli F, Bianchi M, Rovesti M, Roccia MG. Stress and inflammation in coronary artery disease: A review psychoneuroendocrineimmunology-based. Front Immunol 2018;9:2031.
• Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013;31:105-14.
• Alcocer-Gomez E, Cordero MD. NLRP3 inflammasome: common nexus between depression and cardiovascular diseases. Nat Rev Cardiol 2017;14(2):124.
• Hamieh N, Meneton P, Wiernik E, Limosin F, Zins M, Goldberg M, Melchior M, Lemogne C. Depression, treatable cardiovascular risk factors and incident cardiac events in the Gazel cohort. Int J Cardiol 2019;284:90-95.
• Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun 2018;70:61-75.
• Castro AR, Silva SO, Soares SC. The use of high sensitivity C-reactive protein in cardiovascular disease detection. J Pharm Pharm Sci 2018;21(1):496-503.
• Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 2011;123(1):114-9.
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
• Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71(2):171-86.
• Davidson KW, Schwartz JE, Kirkland SA, Mostofsky E, Fink D, Guernsey D, Shimbo D. Relation of inflammation to depression and incident coronary heart disease (from the Canadian Nova Scotia Health Survey [NSHS95] Prospective Population Study). Am J Cardiol 2009;103(6):755-61.
• Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA Psychiatry 2013;70(2):176-84.
• Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry. 2012;71(1):15-21.
• Elovainio M, Aalto AM, Kivimäki M, Pirkola S, Sundvall J, Lönnqvist J, Reunanen A. Depression and C-reactive protein: population-based Health 2000 Study. Psychosom Med 2009;71(4):423-30.
• Nadrowski P, Chudek J, Skrzypek M, Puzianowska-Kuźnicka M, Mossakowska M, Więcek A, Zdrojewski T, Grodzicki T, Kozakiewicz K. Associations between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly. Exp Gerontol 2016;85:112-117.
• Tayefi M, Shafiee M, Kazemi-Bajestani SMR, Esmaeili H, Darroudi S, Khakpouri S, Mohammadi M, Ghaneifar Z, et al. Depression and anxiety both associate with serum level of hs-CRP: a gender-stratified analysis in a population-based study. Psychoneuroendocrinology. 2017;81:63-69.
• Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med 2019;49(12):1958-1970.
• Hiles SA, Baker AL, de Malmanche T, Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42(10):2015-26.
• Eyre HA, Lavretsky H, Kartika J, Qassim A, Baune BT. Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. Pharmacopsychiatry. 2016;49(3):85-96.
• Więdłocha M, Marcinowicz P, Krupa R, Janoska-Jaździk M, Janus M, Dębowska W, Mosiołek A, Waszkiewicz N, Szulc A. Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018;80(Pt C):217-226.